Claims for Patent: 7,842,790
✉ Email this page to a colleague
Summary for Patent: 7,842,790
Title: | Antibodies against human parathyroid hormone related protein |
Abstract: | Disclosed are an antibody against human para-thyroid-hormone-related protein, a DNA coding for the antibody, a recombinant vector containing the DNA, a transformant transformed with the recombinant vector, a method for preparation of the antibody, and uses of the antibody. |
Inventor(s): | Sato; Koh (Gotenba, JP), Wakahara; Yuji (Gotenba, JP), Yabuta; Naohiro (Gotenba, JP) |
Assignee: | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) |
Application Number: | 11/931,429 |
Patent Claims: | 1. An agent for improving at least one of the symptoms of hypercalcemia associated with malignant tumor, said agent comprising as an active ingredient an antibody that
specifically binds to and at least partially neutralizes human parathyroid hormone related protein (1-34) [PTHrP (1-34)] comprising the amino acid sequence of SEQ ID NO: 75, wherein said antibody comprises a heavy (H) chain variable (V) region comprising
complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs: 62-64 and a light (L) chain V region comprising CDRs comprising the amino acid sequences of SEQ ID NOs: 59-61.
2. The agent according to claim 1, wherein the antibody is a humanized or chimeric antibody. 3. The agent according to claim 1, wherein the malignant tumor is at least one selected from the group consisting of cancers of the pancreas, lung, pharynx, larynx, tongue, gingiva, esophagus, stomach, binary duct, breast, kidney, urinary bladder, uterus and prostate, and malignant lymphoma. 4. The agent according to claim 1, wherein the antibody is a chimeric antibody, which comprises a L chain polypeptide comprising an L chain C region of a human antibody and an L chain V region of a mouse monoclonal antibody against said human PTHrP (1-34) comprising said L chain V region comprising CDRs comprising the amino acid sequences of SEQ ID NOs: 59-61, and a H chain polypeptide comprising an H chain C region of a human antibody and an H chain V region of a mouse monoclonal antibody against said human PTHrP (1-34) comprising said H chain V region comprising CDRs comprising the amino acid sequences of SEQ ID NOs: 62-64. 5. The agent according to claim 4, comprising said chimeric antibody comprises a chimeric L chain comprising an L chain V region comprising the amino acid sequence as shown in SEQ ID NO:45, and a chimeric H chain comprising an H chain V region comprising the amino acid sequence as shown in SEQ ID NO:46. 6. The agent according to claim 1, wherein the antibody is a humanized antibody. 7. The agent according to claim 6, wherein the humanized antibody comprises an L chain polypeptide comprising an L chain C region of a human antibody and an L chain V region comprising framework regions 1 to 4 of an L chain V region of a human antibody and CDRs 1 to 3 of an L chain V region of a mouse monoclonal antibody against said human PTHrP (1-34) comprising said H chain V region comprising CDRs comprising the amino acid sequences of SEQ ID NOs: 59-61; and an H chain polypeptide comprising an H chain C region of a human antibody and an H chain V region comprising framework regions 1 to 4 of an H chain V region of a human antibody and CDRs 1 to 3 of an H chain V region of a mouse monoclonal antibody against said human PTHrP (1-34) comprising said H chain V region comprising CDRs comprising the amino acid sequences of SEQ ID NOs: 62-64. 8. The agent according to claim 7, wherein the L chain V region of the L chain of said humanized antibody comprises the amino acid sequence as shown in any one of SEQ ID NOs: 48-51. 9. The agent according to claim 7, wherein the L chain V region of the L chain of said humanized antibody comprises the amino acid sequence as shown in any one of SEQ ID NOs: 52-55. 10. The agent according to claim 7, wherein the H chain V region of the H chain of said humanized antibody comprises the amino acid sequence as shown in SEQ ID NO: 56. 11. The agent according to claim 7, wherein said humanized antibody is a humanized version of the mouse monoclonal antibody #23-57-137-1 produced by the hybridoma clone deposited under FERM Accession No. BP-5631. |
Details for Patent 7,842,790
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2016-09-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.